Literature DB >> 23684145

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.

Sandra J Taler1, Rajiv Agarwal, George L Bakris, Joseph T Flynn, Peter M Nilsson, Mahboob Rahman, Paul W Sanders, Stephen C Textor, Matthew R Weir, Raymond R Townsend.   

Abstract

In response to the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for blood pressure management in patients with chronic kidney disease not on dialysis, the National Kidney Foundation organized a group of US experts in hypertension and transplant nephrology to review the recommendations and comment on their relevancy in the context of current US clinical practice and concerns. The overriding message was the dearth of clinical trial evidence to provide strong evidence-based recommendations. For patients with CKD with normal to mildly increased albuminuria, goal blood pressure has been relaxed to ≤140/90 mm Hg for both diabetic and nondiabetic patients. In contrast, KDIGO continues to recommend goal blood pressure ≤130/80 mm Hg for patients with chronic kidney disease with moderately or severely increased albuminuria and for all renal transplant recipients regardless of the presence of proteinuria, without supporting data. The expert panel thought the KDIGO recommendations were generally reasonable but lacking in sufficient evidence support and that additional studies are greatly needed.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kidney Disease: Improving Global Outcomes (KDIGO); blood pressure; guideline

Mesh:

Year:  2013        PMID: 23684145      PMCID: PMC3929429          DOI: 10.1053/j.ajkd.2013.03.018

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  35 in total

1.  K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2004-05       Impact factor: 8.860

2.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

3.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.

Authors:  F M Sacks; L P Svetkey; W M Vollmer; L J Appel; G A Bray; D Harsha; E Obarzanek; P R Conlin; E R Miller; D G Simons-Morton; N Karanja; P H Lin
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

4.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

5.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Authors:  L Y Agodoa; L Appel; G L Bakris; G Beck; J Bourgoignie; J P Briggs; J Charleston; D Cheek; W Cleveland; J G Douglas; M Douglas; D Dowie; M Faulkner; A Gabriel; J Gassman; T Greene; Y Hall; L Hebert; L Hiremath; K Jamerson; C J Johnson; J Kopple; J Kusek; J Lash; J Lea; J B Lewis; M Lipkowitz; S Massry; J Middleton; E R Miller; K Norris; D O'Connor; A Ojo; R A Phillips; V Pogue; M Rahman; O S Randall; S Rostand; G Schulman; W Smith; D Thornley-Brown; C C Tisher; R D Toto; J T Wright; S Xu
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

6.  Body weight-for-height relationships predict mortality in maintenance hemodialysis patients.

Authors:  J D Kopple; X Zhu; N L Lew; E G Lowrie
Journal:  Kidney Int       Date:  1999-09       Impact factor: 10.612

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Antiproteinuric effects of enalapril and losartan: a pilot study.

Authors:  Colin Thomas White; Catherine Fiona Macpherson; Robert Morrison Hurley; Douglas George Matsell
Journal:  Pediatr Nephrol       Date:  2003-08-12       Impact factor: 3.714

9.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

10.  The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

View more
  59 in total

Review 1.  [Diabetic kidney disease - Update 2016].

Authors:  Harald Sourij; Roland Edlinger; Friedrich Prischl; Martin Auinger; Alexandra Kautzky-Willer; Marcus D Säemann; Rudolf Prager; Martin Clodi; Guntram Schernthaner; Gert Mayer; Rainer Oberbauer; Alexander R Rosenkranz
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

Review 2.  Practical use of home blood pressure monitoring in chronic kidney disease.

Authors:  Sarah Sanghavi; Joseph A Vassalotti
Journal:  Cardiorenal Med       Date:  2014-06-04       Impact factor: 2.041

3.  BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.

Authors:  David J Leehey; Jane H Zhang; Nicholas V Emanuele; Adam Whaley-Connell; Paul M Palevsky; Robert F Reilly; Peter Guarino; Linda F Fried
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-19       Impact factor: 8.237

4.  Nephrotic range proteinuria as a strong risk factor for rapid renal function decline during pre-dialysis phase in type 2 diabetic patients with severely impaired renal function.

Authors:  Yuichiro Kitai; Yohei Doi; Keisuke Osaki; Sayaka Sugioka; Masao Koshikawa; Akira Sugawara
Journal:  Clin Exp Nephrol       Date:  2015-02-15       Impact factor: 2.801

Review 5.  [Chronic kidney disease : What is currently available for treatment?]

Authors:  S Fleig; M Patecki; R Schmitt
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

Review 6.  Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.

Authors:  Rakesh Malhotra; Hoang Anh Nguyen; Oscar Benavente; Mihriye Mete; Barbara V Howard; Jonathan Mant; Michelle C Odden; Carmen A Peralta; Alfred K Cheung; Girish N Nadkarni; Ruth L Coleman; Rury R Holman; Alberto Zanchetti; Ruth Peters; Nigel Beckett; Jan A Staessen; Joachim H Ix
Journal:  JAMA Intern Med       Date:  2017-10-01       Impact factor: 21.873

Review 7.  Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment.

Authors:  Paul Muntner; Paul K Whelton
Journal:  J Am Coll Cardiol       Date:  2017-05-16       Impact factor: 24.094

Review 8.  Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

Authors:  Collen Majewski; George L Bakris
Journal:  Curr Diab Rep       Date:  2016-04       Impact factor: 4.810

Review 9.  Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.

Authors:  Vijay Shivaswamy; Brian Boerner; Jennifer Larsen
Journal:  Endocr Rev       Date:  2015-12-09       Impact factor: 19.871

Review 10.  The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.

Authors:  Tao Yang; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  Nat Rev Nephrol       Date:  2018-07       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.